Donna M. Neumann

TL;DR: The structure of the anticancer agent 4,4'-dihydroxybenzophenone-2,4-dinitrophenylhydrazone (A-007) has been modified through SAR and by incorporating barbituric acid, pyridine, quinoline, and alkylcarboxylic acids into A-007's moieties.

TL;DR: Recent advances in ocular drug delivery methods and the development of novel biopharmaceutical agents could lead to new regimens for the treatment of disease of the posterior retina, choroids, and macula.

TL;DR: Basic HSV-1 virology is highlighted, animal models of latency, reactivation, and recurrent ocular disease to the current clinical data are compared, and the development of therapies that would reduce asymptomatic viral shedding and lower the risks of recurrent disease and transmission of the virus is key to decreasing the morbidity of ocular herpetic disease.

TL;DR: Antifungal activity of the prepared analogs showed that salicylaldehyde hydrazones and hydrazides are potent inhibitors of fungal growth with little to no mammalian cell toxicity, making these analogs promising new targets for future therapeutic development.

TL;DR: Infection of human primary neural cells with a high phenotypic reactivator HSV-1 induces upregulation of a brain-enriched microRNA-146a that is associated with proinflammatory signaling in stressed brain cells and Alzheimer's disease, and the activation of key elements of the arachidonic acid cascade known to contribute to Alzheimer-type neuropathological change are suggested.